ERS Genomics

Activities: Manufacturing Research & Development Analysis

Trending Articles

  1. Solvent recycler SPR-200 boosts sustainability in pharma labs Recycling up to 90% of solvent in isocratic HPLC improves lab efficiency and sustainability
  2. IFF Pharma Solutions launches customer experience platform, AnswerCenter AnswerCenter is part of IFF's ongoing digitalisation initiative, allowing customers to easily access tailored pharmaceutical excipient solutions
  3. Nipro and Owen Mumford partner to distribute drug delivery device, UniSafe The medical device is a patient-centric method for the delivery of injectable medicines, and is designed to enhance compliance
  4. Neuraxpharm Group and Pharmathen partner to develop long-lasting psychiatric injectables The co-development deal aims to enhance patient compliance, with Pharmathen and Neuraxpharm holding rights to the product in North America and Europe, respectively
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    CDMO insights: development and manufacture of a highly potent OSD product In today’s pharmaceutical landscape, contract development and manufacturing organisations (CDMOs) are ubiquitous. Prior to the CDMO boom in the 1990s, however, this wasn’t...

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

Related Content

Research & Development

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering
Cell & Gene Therapy

ERS Genomics appoints John E Milad as CEO

John brings more than 25 years of experience into the role, with a majority of his career being in the life sciences industry as a venture capitalist and investment banker
Cell & Gene Therapy

CRISPR patent upheld by CNIPA

Patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge
Regulatory

Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office

Patent JP6692856 upheld for second time in response to invalidation challenge
Research & Development

CET licenses CRISPR/Cas9 portfolio from ERS Genomics

ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier
Finance

ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement

ERS Genomics holds an exclusive license from Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory

ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement

ERS Genomics holds the exclusive license from co-founder Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Subscribe now